TABLE 2

Main characteristics of patients (forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7) and controls (FEV1/FVC≥0.7) included in the ECLIPSE study

PatientsControlsp-value
Subjects n119124
Demographics and exposure history
 Age years47.3±2.745.7±3.0<0.001
 Males61%52%0.162
 Body mass index kg·m−226.5±6.926.1±4.60.650
 Cumulative smoking exposure pack-years34.5±17.024.7±11.7<0.001
 Current smokers38%23%0.014
Family history and early-life events
 Familiar asthma24%19%0.342
 Familiar bronchitis34%15%0.001
 Familiar emphysema29%8%<0.001
 Familiar hypertension49%48%1
Symptoms
 mMRC score ≥213%1%0.001
Previous treatments and use of healthcare resources
 Oral Corticosteroid use2%0%0.460
 Number of exacerbations0.7± 0.9NA
Physiology
 FEV1/FVC (post-bd) %49.0± 11.880.1±4.9<0.001
 FEV1 (post-bd) % ref.49.0± 18.2103.9±10.8<0.001
 FVC (post-bd) % ref.82.5± 22.1112.8±12.6<0.001
 Total lung capacity % ref.114.0± 17.5102.79±11.4<0.001
 6MWD test
  Distance walked m425.6±137.7NA
Imaging
 Presence of CT emphysema n (%)60%8%<0.001
Biomarkers
 Basophils (%)0.33± 0.230.32± 0.240.527
 Eosinophils (%)2.6± 2.12.55± 1.580.464
 Haematocrit0.44±0.040.43± 0.040.009
 Lymphocytes (%)28.04± 8.6130.22± 7.110.024
 Monocytes (%)5.96± 2.495.76± 2.230.682
 Segmented neutrophils (%)63.06± 9.5261.15± 8.290.102
 Total neutrophils (total ANC)5.23± 2.24.71± 1.950.050
 Total neutrophils (%)63.06± 9.5261.15± 8.290.102
 White blood cells ×109/L8.11± 2.497.56± 2.370.057

Results are presented as mean±sd or proportion. p-values <0.05 are highlighted in bold text. mMRC: modified Medical Research Council scale; post-bd: post-bronchodilator; % ref.: % of reference value; 6MWD: 6-min walk test; CT: computed tomography; ANC: total absolute neutrophil count.